OBJECTIVES: Neuropathic pain (NP) is a common disorder which can be chronic, severe, and disabling and is associated with reductions in quality of life and considerable costs. Current first-line treatments for NP include tricyclic antidepressants and anti-convulsants. QUTENZA® is a cutaneous patch that allows rapid dermal delivery of capsaicin directly to the source of pain. The objective of this analysis is to estimate the burden of NP, current treatment costs and the budget impact of introducing QUTENZA® for the treatment of peripheral NP in non-diabetic adults in Sweden. METHODS: We constructed a budget impact calculator to estimate the impact of introducing QUTENZA® for 100 people in Sweden. Drug costs for each management strategy are annual costs, based on estimated market shares, and range from SEK 231 to SEK 5,806 (with SEK 3,909 for QUTENZA®). We assumed a 50% uptake of QUTENZA® and a 50% reduction in the use of concomitant medication in the model, based on evidence from real-world data. RESULTS: For a NP population of n=100, the cost of current prescribing was estimated at SEK 1.00 million. The cost of alternative prescribing including QUTENZA® was estimated at SEK 1.01 million. The annual cost of treating a patient with QUTENZA® was estimated as SEK 11,941. The estimated cumulative budget impact by year (for 100 patients, with the market share rising from 10% in Year 1 to 100% in Year 5) ranged from SEK 9,664 in Year 1 to SEK 67,949 in Year 5. CONCLUSIONS: The introduction of QUTENZA® results in a budget impact of SEK 67,949 for 100 patients over 5 years. This represents a minimal additional expenditure and could be considered good value for money given the added benefits for patients with NP in Sweden.